2 blue chip ASX 200 analysts assess buys
Image source: Getty Images
Investors looking to bolster their portfolio with blue chip ASX 200 stocks may want to look at both below.
Here’s why these top-notch ASX 200 stocks are considered buys:
The first top-notch ASX 200 action to look at is BHP. Big Australian shares have fallen significantly recently following a sharp drop in the price of iron ore.
However, it should be noted that the price of the steel ingredient is still significantly higher than the production costs of the mining giant.
It also has diversified activities and benefits from the rise in the prices of other raw materials.
Macquarie remains very positive about the company. In fact, earlier this week the broker gave BHP shares an outperformance rating and a price target of $ 55.00. Its analysts are also forecasting generous dividend payments in the years to come.
Another ASX 200 stock to look at is this medical device company focused on treating sleep.
Over the past decade, ResMed has grown into one of the leaders in the sleep therapy market. This is explained by its high level of investment in R&D and acquisitions. Together, the company now has a portfolio of leading hardware and software products.
This leaves him in a good position to take advantage of the growing market for sleep treatments. Management estimates that there are around 1 billion people with sleep apnea worldwide, with only around 20% of those people currently diagnosed.
ResMed also appears well positioned to benefit from the move to home care and a significant product recall from a key competitor.
Credit Suisse is a ResMed fan. Last week, the broker maintained its outperformance rating and raised its price target on the company’s shares to $ 44.00. He believes ResMed is well positioned to grow at rates above the industry. The broker also believes that the market is underestimating the potential market share gains it will derive from the aforementioned product recall.